{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:54:23Z","timestamp":1779195263747,"version":"3.51.4"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":2664,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T00:00:00Z","timestamp":1538611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17K16015"],"award-info":[{"award-number":["17K16015"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17K16015"],"award-info":[{"award-number":["17K16015"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Mutant transthyretin (ATTRm) amyloidosis is a systemic disease caused by the deposition of amyloid fibrils derived from mutated transthyretin. Although cardiac involvement impacts the prognosis of patients with ATTRm amyloidosis, the incidence of cardiac events, such as bradyarrhythmia, ventricular tachycardia, and heart failure, has not been fully elucidated. The aim of this study was to evaluate the prognosis and predictors of clinical outcomes, including cardiac events, in patients with ATTRm amyloidosis in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We evaluated 90 consecutive patients with ATTRm amyloidosis at Kumamoto University. ATTRm amyloidosis was diagnosed by the observation of both amyloid fibril deposition on tissue biopsy and a transthyretin mutation on sequential analysis. Sympathetic nerve activity was evaluated in 59 patients using 123-iodine metaiodobenzylguanidine (123I-MIBG) imaging. The endpoint was a composite of all-cause death, hospitalization for heart failure, and implantation of a pacemaker, implantable cardioverter defibrillator, or cardiac resynchronization therapy defibrillator. Sixty-seven patients had the Val30Met mutation (74%). The composite endpoint occurred in 23 patients (26%): all-cause death (n = 6), hospitalization for worsening heart failure (n = 1), and implantation of an implantable cardioverter defibrillator (n = 6), cardiac resynchronization therapy defibrillator (n = 3), or pacemaker (n = 7). The 5-year incident rate for clinical outcomes was 19%. In a multivariate Cox hazard analysis, age [hazard ratio (HR): 1.07, 95% confidence interval (95% CI): 1.01\u20131.12, P = 0.015], PQ interval (HR: 1.01, 95% CI: 1.00\u20131.02, P = 0.042), interventricular septum thickness in diastole (HR: 1.25, 95% CI: 1.09\u20131.42, P = 0.001), and non-Val30Met mutation (HR: 4.31, 95% CI: 1.53\u201312.16, P = 0.006) were independent predictive factors of clinical outcomes. Kaplan\u2013Meier analysis demonstrated a significantly higher probability of the composite endpoint in the non-Val30Met group than in the Val30Met group (log-rank test: P = 0.002) and in patients with left ventricular hypertrophy than in patients without left ventricular hypertrophy (log-rank test: P &amp;lt; 0.001). In patients who underwent 123I-MIBG imaging, a delayed heart-to-mediastinum (HM) ratio &amp;lt;1.6 was a significant predictive factor of the composite endpoint (HR: 4.98, 95% CI: 1.73\u201314.37, P = 0.003) in the univariate Cox hazard analyses. Kaplan\u2013Meier curve analysis showed that a delayed HM ratio &amp;lt;1.6 was associated with a poor prognosis (log-rank test: P = 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Non-Val30Met mutation, septal hypertrophy, and a delayed HM ratio are useful predictors of clinical outcomes in patients with ATTRm amyloidosis in Japan. These results suggest that it is important to evaluate cardiac involvement in terms of morphological (left ventricular hypertrophy) and functional (cardiac denervation) perspectives using echocardiography and 123I-MIBG imaging, respectively.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.12361","type":"journal-article","created":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T16:43:26Z","timestamp":1538757806000},"page":"122-130","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Non-Val30Met Mutation, Septal Hypertrophy, and Cardiac Denervation in Patients with Mutant Transthyretin Amyloidosis"],"prefix":"10.1093","volume":"6","author":[{"given":"Kyoko","family":"Hirakawa","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University , Kumamoto ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Takashio","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University , Kumamoto ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyohei","family":"Marume","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University , Kumamoto ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University , Kumamoto ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Hanatani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University , Kumamoto ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University , Kumamoto ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University , Kumamoto ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Izumiya","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University , Kumamoto ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Kaikita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University , Kumamoto ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seitaro","family":"Oda","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, Graduate School of Medical Sciences, Kumamoto University , Kumamoto ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Utsunomiya","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, Graduate School of Medical Sciences, Kumamoto University , Kumamoto ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Shiraishi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, Graduate School of Medical Sciences, Kumamoto University , Kumamoto ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuharu","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medical Sciences, Kumamoto University , Kumamoto ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medical Sciences, Kumamoto University , Kumamoto ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, Graduate School of Medical Sciences, Kumamoto University , Kumamoto ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medical Sciences, Kumamoto University , Kumamoto ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Tsujita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University , Kumamoto ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,10,4]]},"reference":[{"key":"2026012115101455900_ehf212361-bib-0001","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM199709253371306","article-title":"The systemic amyloidoses","volume":"337","author":"Falk","year":"1997","journal-title":"N Engl J Med"},{"key":"2026012115101455900_ehf212361-bib-0002","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002877","article-title":"Subtype-specific interactions and prognosis in cardiac amyloidosis","volume":"5","author":"Sperry","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2026012115101455900_ehf212361-bib-0003","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"2026012115101455900_ehf212361-bib-0004","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2047-9158-3-19","article-title":"Recent advances in transthyretin amyloidosis therapy","volume":"3","author":"Ueda","year":"2014","journal-title":"Transl Neurodegener"},{"key":"2026012115101455900_ehf212361-bib-0005","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00415-017-8640-7","article-title":"Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan","volume":"265","author":"Yamashita","year":"2018","journal-title":"J Neurol"},{"key":"2026012115101455900_ehf212361-bib-0006","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","article-title":"Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments","volume":"86","author":"Sekijima","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026012115101455900_ehf212361-bib-0007","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026012115101455900_ehf212361-bib-0008","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2016.05.020","article-title":"Transthyretin amyloidosis","volume":"68","author":"Semigran","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026012115101455900_ehf212361-bib-0009","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jcmg.2014.03.002","article-title":"Noninvasive risk stratification of patients with transthyretin amyloidosis","volume":"7","author":"Kristen","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012115101455900_ehf212361-bib-0010","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jjcc.2017.10.003","article-title":"Recent advances in diagnosis and treatment of cardiac amyloidosis","volume":"71","author":"Izumiya","year":"2018","journal-title":"J Cardiol"},{"key":"2026012115101455900_ehf212361-bib-0011","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.amjcard.2017.09.029","article-title":"Frequency of and prognostic significance of cardiac involvement at presentation in hereditary transthyretin-derived amyloidosis and the value of N-terminal pro-B-type natriuretic peptide","volume":"121","author":"Klaassen","year":"2018","journal-title":"Am J Cardiol"},{"key":"2026012115101455900_ehf212361-bib-0012","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1161\/CIRCIMAGING.112.000367","article-title":"Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy","volume":"6","author":"Coutinho","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026012115101455900_ehf212361-bib-0013","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1006\/bbrc.1996.1685","article-title":"A new simple and rapid screening method for variant transthyretin-related amyloidosis","volume":"228","author":"Ando","year":"1996","journal-title":"Biochem Biophys Res Commun"},{"key":"2026012115101455900_ehf212361-bib-0014","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"key":"2026012115101455900_ehf212361-bib-0015","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s12350-014-9916-2","article-title":"Multicenter cross-calibration of I-123 metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera-collimator variations","volume":"21","author":"Nakajima","year":"2014","journal-title":"J Nucl Cardiol"},{"key":"2026012115101455900_ehf212361-bib-0016","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00259-011-1963-1","article-title":"Standardization of metaiodobenzylguanidine heart to mediastinum ratio using a calibration phantom: effects of correction on normal databases and a multicentre study","volume":"39","author":"Nakajima","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026012115101455900_ehf212361-bib-0017","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijcard.2016.07.254","article-title":"Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis","volume":"222","author":"Hamon","year":"2016","journal-title":"Int J Cardiol"},{"key":"2026012115101455900_ehf212361-bib-0018","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1093\/eurheartj\/eht150","article-title":"2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA)","volume":"34","author":"Brignole","year":"2013","journal-title":"Eur Heart J"},{"key":"2026012115101455900_ehf212361-bib-0019","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS)","volume":"164","author":"Ruberg","year":"2012","journal-title":"Am Heart J"},{"key":"2026012115101455900_ehf212361-bib-0020","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026012115101455900_ehf212361-bib-0021","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0735-1097(96)00438-X","article-title":"Iodine-123 metaiodobenzylguanidine scintigraphic assessment of myocardial sympathetic innervation in patients with familial amyloid polyneuropathy","volume":"29","author":"Tanaka","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"2026012115101455900_ehf212361-bib-0022","first-page":"1040","article-title":"Cardiac sympathetic denervation in transthyretin-related familial amyloidotic polyneuropathy: detection with iodine-123-MIBG","volume":"36","author":"Nakata","year":"1995","journal-title":"J Nucl Med"},{"key":"2026012115101455900_ehf212361-bib-0023","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s002590050406","article-title":"Cardiac sympathetic denervation in familial amyloid polyneuropathy assessed by iodine-123 metaiodobenzylguanidine scintigraphy and heart rate variability","volume":"26","author":"Delahaye","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"2026012115101455900_ehf212361-bib-0024","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"2026012115101455900_ehf212361-bib-0025","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"2026012115101455900_ehf212361-bib-0026","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N Engl J Med"},{"key":"2026012115101455900_ehf212361-bib-0027","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/CIRCHEARTFAILURE.113.000890","article-title":"Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes","volume":"8","author":"Maurer","year":"2015","journal-title":"Circ Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fehf2.12361","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/chorus\/v1\/articles\/10.1002%2Fehf2.12361","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/6\/1\/122\/66135700\/eschf_6_1_122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/6\/1\/122\/66135700\/eschf_6_1_122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:13:14Z","timestamp":1769026394000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/6\/1\/122\/8403627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,4]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,10,4]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12361","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2]]},"published":{"date-parts":[[2018,10,4]]},"assertion":[{"value":"2018-04-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}